Johnson & Johnson Q3
This article was originally published in The Rose Sheet
Executive Summary
Worldwide skin care sales advance 15% to $390 mil. in third quarter, led by Neutrogena, Aveeno, Clean & Clear brands, firm says in 1Oct. 15 sales and earnings release. Skin care sales in the U.S. rose 13% to $170 mil. and were up 17% to $169 mil. in international markets. "Continued strength of the overall product line, momentum associated with a broad range of new product offerings launched earlier this year and expanded growth of these equities outside the U.S. were the key drivers" of growth, according to J&J. Baby and kids care sales rose 4% worldwide to $300 mil., reflecting strong sales outside the U.S. of skin care and wipes products. Domestic baby care sales declined 3% to $68 mil., depressed by divestiture of Healthflow and Sippy Cup businesses...
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.